TORONTO--(BUSINESS WIRE)--Alternate Health Corp (CSE:AHG) (OTC:AHGIF), a leader in complementary medicine and patient-focused healthcare, today announced an update and clarification on the first-ever Continuing Medical Education (CME) course approved for AMA PRA Category 1 Credit(s)TM regarding treatments of Chronic Traumatic Encephalopathy (CTE), including Cannabis.
This course has been created in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Alternate Health Corp.
Alternate Health Corp wishes to stress that neither the American Medical Association (AMA) nor the ACCME have in any way approved cannabis or cannabis related products or treatments in conjunction with Alternate Health Corp. education programs or its public announcements. Alternate Health’s CME courses are designed to meet the certification requirements of the ACCME but such certification does not comment on or imply any direct endorsements of cannabis products or cannabis treatments by this organizations.
About Alternate Health Corp.
Alternate Health Corp is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company’s assets in exclusive patents and partnerships, Alternate Health’s goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.